- Home
- SGLY vs VIVS Comparison
SGLY vs VIVS Comparison
Compare SGLY & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- VIVS
- Stock Information
- Founded
- SGLY 2001
- VIVS 2007
- Country
- SGLY United States
- VIVS United States
- Employees
- SGLY N/A
- VIVS N/A
- Industry
- SGLY
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGLY
- VIVS Health Care
- Exchange
- SGLY Nasdaq
- VIVS Nasdaq
- Market Cap
- SGLY 4.0M
- VIVS 4.7M
- IPO Year
- SGLY 2008
- VIVS N/A
- Fundamental
- Price
- SGLY $1.07
- VIVS $2.11
- Analyst Decision
- SGLY
- VIVS
- Analyst Count
- SGLY 0
- VIVS 0
- Target Price
- SGLY N/A
- VIVS N/A
- AVG Volume (30 Days)
- SGLY 21.3K
- VIVS 45.8K
- Earning Date
- SGLY 09-02-2025
- VIVS 08-12-2025
- Dividend Yield
- SGLY N/A
- VIVS N/A
- EPS Growth
- SGLY N/A
- VIVS N/A
- EPS
- SGLY N/A
- VIVS N/A
- Revenue
- SGLY $2,172,036.00
- VIVS $142,000.00
- Revenue This Year
- SGLY N/A
- VIVS $42.38
- Revenue Next Year
- SGLY N/A
- VIVS $15.42
- P/E Ratio
- SGLY N/A
- VIVS N/A
- Revenue Growth
- SGLY N/A
- VIVS 94.52
- 52 Week Low
- SGLY $0.54
- VIVS $1.41
- 52 Week High
- SGLY $7.65
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- SGLY 58.38
- VIVS 63.00
- Support Level
- SGLY $0.91
- VIVS $1.72
- Resistance Level
- SGLY $1.17
- VIVS $1.89
- Average True Range (ATR)
- SGLY 0.06
- VIVS 0.13
- MACD
- SGLY 0.01
- VIVS 0.02
- Stochastic Oscillator
- SGLY 61.54
- VIVS 86.96
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.